Optimal indication of neoadjuvant chemoradiotherapy for XXXX .

@entity1 @entity788 @entity136 @entity5
PURPOSE: Much attention has been paid to preoperative treatment as a new strategy especially for borderline resectable @entity788 (BRPC). The purpose of this study was to define the optimal indication of neoadjuvant chemoradiotherapy (NACRT) for @entity788 . METHODS: We analyzed consecutive 184 @entity1 who had undergone pancreatic resection in Nara Medical University Hospital. Resectability status was classified by NCCN guidelines. Full-dose @entity136 with concurrent radiation was used as NACRT. We evaluated 85 @entity1 treated with NACRT in comparison with 99 @entity1 without NACRT as control. RESULTS: The regimen of NACRT was well tolerated and feasible. The perioperative outcomes were almost comparable. The postoperative complications were significantly less frequent in NACRT group than non-NACRT group. The pathological effects on both resectable and borderline @entity5 were favorable in NACRT group compared to non-NACRT group. The overall survival of resectable @entity788 was significantly better than that of BRPC regardless of whether the @entity1 were treated with or without NACRT. The prognosis of the @entity1 with NACRT in resectable @entity5 was significantly better than without, while there was no significant difference in BRPC. Furthermore, multivariate analysis of various factors in the @entity1 with NACRT identified resectability status and completion of adjuvant chemotherapy as independent prognostic factors. CONCLUSIONS: NACRT did not improve the prognosis of the @entity1 with BRPC, although it induced substantial pathological antitumor effect. In contrast, the prognosis of resectable @entity788 treated with NACRT was favorable. Therefore, resectable @entity788 may be good indication for multimodal treatment including NACRT.
